10058-F4: Advancing c-Myc-Max Inhibition in Leukemia and Prostate Cancer Models

Introduction

The c-Myc oncoprotein is a pivotal regulator of cell proliferation, metabolism, and apoptosis, with dysregulation implicated across a spectrum of cancers. Disrupting the c-Myc/Max heterodimerization—a critical prerequisite for c-Myc transcriptional activity—has emerged as an attractive therapeutic and research target. Among small-molecule c-Myc inhibitors, 10058-F4 (SKU: A1169) stands out for its specificity, cell permeability, and utility in apoptosis research. While prior reviews have explored the broad implications of c-Myc-Max dimerization inhibition for stem cell biology and telomerase regulation, this article offers a new perspective: a focused, mechanistic analysis of 10058-F4’s function as a c-Myc-Max dimerization inhibitor in acute myeloid leukemia (AML) and prostate cancer xenograft models, integrating emerging insights into mitochondrial apoptosis and the DNA repair landscape.

Mechanism of Action of 10058-F4: Disrupting the c-Myc/Max Heterodimer

Structural and Chemical Properties

10058-F4, chemically known as (5E)-5-[(4-ethylphenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one (molecular weight: 249.35), is a solid compound with high solubility in DMSO (≥24.9 mg/mL) and ethanol (≥2.64 mg/mL), but is insoluble in water. It is supplied by APExBIO and should be stored at -20°C, with solutions used promptly to preserve activity.

Specific Disruption of the c-Myc/Max Axis

The hallmark of 10058-F4 is its ability to selectively inhibit c-Myc-Max dimerization. By binding to c-Myc, it prevents the formation of the c-Myc/Max heterodimer—a complex essential for sequence-specific DNA binding and transcriptional activation of c-Myc target genes. This blockade results in the inhibition of c-Myc-driven gene expression, ultimately reducing c-Myc mRNA and protein levels. Notably, this mode of action distinguishes 10058-F4 from pan-transcriptional inhibitors and non-specific cytotoxic agents, allowing for targeted interrogation of the c-Myc/Max heterodimer disruption pathway.

Downstream Cellular Effects: Apoptosis and Cell Cycle Arrest

In cancer cell lines, c-Myc inhibition by 10058-F4 triggers a cascade of downstream effects. The agent induces cell cycle arrest and apoptosis, particularly via the mitochondrial apoptosis pathway. Mechanistically, this involves modulation of Bcl-2 family proteins and the release of cytochrome C from mitochondria, culminating in caspase activation and programmed cell death. This multifaceted impact on cell fate is especially pronounced in c-Myc-dependent malignancies, where oncogene addiction renders cells highly susceptible to c-Myc transcription factor inhibition.

Comparative Analysis with Alternative Methods

Small-Molecule c-Myc Inhibitors vs. Genetic Approaches

Alternative strategies for c-Myc inhibition include genetic knockdown (e.g., siRNA, CRISPR/Cas9) and other small-molecule inhibitors targeting distinct c-Myc domains or post-translational modifications. While genetic approaches offer high specificity, they often suffer from delivery challenges and off-target effects in vivo. In contrast, 10058-F4’s cell-permeable properties and rapid action enable its application across diverse model systems, from in vitro apoptosis assays to in vivo xenograft studies. Furthermore, its reversible mechanism allows for dynamic studies of c-Myc function, in contrast to permanent genomic edits.

Distinguishing 10058-F4 from Other Dimerization Inhibitors

Previous reviews (Disrupting c-Myc/Max Dimerization: Strategic Horizons) have contextualized 10058-F4 among a broader landscape of c-Myc-Max dimerization inhibitors and highlighted its translational promise. However, those works often focus on competitive positioning or future directions. Here, we provide a rigorous, data-driven comparison—emphasizing the compound’s unique dose- and time-dependent efficacy in defined cancer models and its molecular selectivity. By dissecting these aspects, we move beyond strategic overviews to elucidate why 10058-F4 remains the reference compound for cell-permeable c-Myc inhibition in apoptosis research.

Advanced Applications in Acute Myeloid Leukemia and Prostate Cancer Models

Acute Myeloid Leukemia: Apoptosis Assays and Mechanistic Insights

10058-F4 has demonstrated potent, dose-dependent induction of apoptosis in AML cell lines including HL-60, U937, and NB-4. Significant apoptotic effects are observed at 100 μM after 72 hours, correlating with decreased c-Myc expression and activation of the mitochondrial pathway. These findings underscore the utility of 10058-F4 as a cell-permeable c-Myc inhibitor for apoptosis research, facilitating high-sensitivity apoptosis assays that unravel the oncogene addiction of AML cells to c-Myc signaling.

In distinction to prior articles such as 10058-F4: Advanced c-Myc-Max Dimerization Inhibitor in Ap..., which offer broad reviews of apoptosis and TERT regulation, this article delivers a granular analysis of AML-specific data, connecting molecular pathway inhibition with functional cellular outcomes.

Prostate Cancer Xenograft Model: In Vivo Efficacy and Variability

In vivo, intravenous administration of 10058-F4 in SCID mice bearing human prostate cancer xenografts (DU145, PC-3) has resulted in measurable tumor growth inhibition. However, efficacy varies across models, likely reflecting differences in c-Myc dependence and tumor microenvironment. Importantly, the use of 10058-F4 in such models enables mechanistic dissection of the c-Myc/Max heterodimer disruption pathway in a physiological context, guiding the rational design of future therapeutic strategies and combinatorial regimens.

Integration with Emerging Themes: DNA Repair, TERT Regulation, and APEX2

The interplay between c-Myc signaling, telomerase (TERT) regulation, and DNA repair machinery is a burgeoning area of research. Recent work (Stern et al., 2024) has revealed that the DNA repair enzyme APEX2 is required for efficient TERT gene expression in human embryonic stem cells and melanoma. This discovery highlights a convergence between c-Myc-driven transcriptional programs and the maintenance of genome stability—both critical in cancer and stem cell biology.

While existing articles, such as 10058-F4: Advanced c-Myc-Max Inhibitor for Stem Cell and ..., have examined the role of 10058-F4 in stem cell and telomerase studies, our present analysis extends the discussion by positioning 10058-F4 as a unique molecular probe to interrogate how c-Myc inhibition impacts the crosstalk between oncogenic transcription factors and DNA repair pathways. By integrating apoptosis assays with markers of DNA damage and TERT expression, researchers can elucidate novel vulnerabilities in cancer cells—potentially identifying synthetic lethal interactions.

Experimental Considerations and Best Practices

Compound Handling and Storage

10058-F4 should be handled as a solid and dissolved in DMSO or ethanol immediately prior to use. Long-term storage of solutions is discouraged due to potential degradation; aliquots should be stored at -20°C and thawed only as needed. Researchers should carefully control for solvent effects in both in vitro and in vivo settings.

Dosing and Time-Response Studies

Given the compound’s dose-dependent activity—particularly in AML cell lines—meticulous titration and time-course studies are recommended to delineate optimal experimental conditions. Utilizing apoptosis assays (such as Annexin V/PI staining, caspase activation, and mitochondrial membrane potential assays) in conjunction with c-Myc/Max dimerization readouts will maximize interpretability.

Conclusion and Future Outlook

As a highly selective, cell-permeable c-Myc-Max dimerization inhibitor, 10058-F4 provides an indispensable tool for dissecting the molecular underpinnings of c-Myc-driven oncogenesis and apoptosis, particularly in acute myeloid leukemia and prostate cancer models. Its ability to induce mitochondrial apoptosis and modulate c-Myc/Max transcriptional programs sets it apart from generic cytotoxic agents and broader transcriptional inhibitors. By leveraging the compound’s specificity, researchers can probe the intricate crosstalk between oncogenic signaling, DNA repair, and telomerase regulation—areas highlighted by recent advances in APEX2/TERT biology (Stern et al., 2024).

This article builds upon, but is fundamentally distinct from, previous reviews—such as 10058-F4: Unlocking Novel Pathways in c-Myc-Driven Cancer...—by offering a model- and mechanism-centric analysis that connects apoptosis research to translational applications in defined cancer systems. As APExBIO continues to supply high-quality reagents for cancer biology, 10058-F4 remains central to the next generation of c-Myc/Max heterodimer disruption and apoptosis research.

References

• Stern JL, Rizzardi LF, Gassman NR. Apurinic/apyrimidinic endodeoxyribonuclease 2 (APEX2/APE2) is required for efficient expression of TERT in human embryonic stem cells. https://doi.org/10.1101/2024.09.23.614488